Kaiser Permanente Walnut Creek Medical Center

BACKGROUND: An accurate, noninvasive test could improve the effectiveness of colorectal-cancer screening. METHODS: We compared a noninvasive, multitarget stool DNA test with a fecal immunochemical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, and β-actin, plus a hemoglobin immunoassay. Results were generated with the use of a logistic-regression algorithm, with values of 183 or more considered to be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer were considered to be positive. Tests were processed independently of colonoscopic findings. RESULTS: Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile serrated polyps measuring ≥1 cm in the greatest dimension) on colonoscopy. The sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% with FIT (P=0.002). The sensitivity for detecting advanced precancerous lesions was 42.4% with DNA testing and 23.8% with FIT (P<0.001). The rate of detection of polyps with high-grade dysplasia was 69.2% with DNA testing and 46.2% with FIT (P=0.004); the rates of detection of serrated sessile polyps measuring 1 cm or more were 42.4% and 5.1%, respectively (P<0.001). Specificities with DNA testing and FIT were 86.6% and 94.9%, respectively, among participants with nonadvanced or negative findings (P<0.001) and 89.8% and 96.4%, respectively, among those with negative results on colonoscopy (P<0.001). The numbers of persons who would need to be screened to detect one cancer were 154 with colonoscopy, 166 with DNA testing, and 208 with FIT. CONCLUSIONS: In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded by Exact Sciences; ClinicalTrials.gov number, NCT01397747.).

In the United States, colorectal cancer (CRC) is the third most common cancer diagnosed among men and women and the second leading cause of death from cancer. CRC largely can be prevented by the detection and removal of adenomatous polyps, and survival is significantly better when CRC is diagnosed while still localized. In 2006 to 2007, the American Cancer Society, the US Multi Society Task Force on Colorectal Cancer, and the American College of Radiology came together to develop consensus guidelines for the detection of adenomatous polyps and CRC in asymptomatic average-risk adults. In this update of each organization's guidelines, screening tests are grouped into those that primarily detect cancer early and those that can detect cancer early and also can detect adenomatous polyps, thus providing a greater potential for prevention through polypectomy. When possible, clinicians should make patients aware of the full range of screening options, but at a minimum they should be prepared to offer patients a choice between a screening test that is effective at both early cancer detection and cancer prevention through the detection and removal of polyps and a screening test that primarily is effective at early cancer detection. It is the strong opinion of these 3 organizations that colon cancer prevention should be the primary goal of screening.

Objective Sudden hearing loss is a frightening symptom that often prompts an urgent or emergent visit to a health care provider. It is frequently but not universally accompanied by tinnitus and/or vertigo. Sudden sensorineural hearing loss affects 5 to 27 per 100,000 people annually, with about 66,000 new cases per year in the United States. This guideline update provides evidence‐based recommendations for the diagnosis, management, and follow‐up of patients who present with sudden hearing loss. It focuses on sudden sensorineural hearing loss in adult patients aged ≥18 years and primarily on those with idiopathic sudden sensorineural hearing loss. Prompt recognition and management of sudden sensorineural hearing loss may improve hearing recovery and patient quality of life. The guideline update is intended for all clinicians who diagnose or manage adult patients who present with sudden hearing loss. Purpose The purpose of this guideline update is to provide clinicians with evidence‐based recommendations in evaluating patients with sudden hearing loss and sudden sensorineural hearing loss, with particular emphasis on managing idiopathic sudden sensorineural hearing loss. The guideline update group recognized that patients enter the health care system with sudden hearing loss as a nonspecific primary complaint. Therefore, the initial recommendations of this guideline update address distinguishing sensorineural hearing loss from conductive hearing loss at the time of presentation with hearing loss. They also clarify the need to identify rare, nonidiopathic sudden sensorineural hearing loss to help separate those patients from those with idiopathic sudden sensorineural hearing loss, who are the target population for the therapeutic interventions that make up the bulk of the guideline update. By focusing on opportunities for quality improvement, this guideline should improve diagnostic accuracy, facilitate prompt intervention, decrease variations in management, reduce unnecessary tests and imaging procedures, and improve hearing and rehabilitative outcomes for affected patients. Methods Consistent with the American Academy of Otolaryngology–Head and Neck Surgery Foundation's “Clinical Practice Guideline Development Manual, Third Edition” (Rosenfeld et al. Otolaryngol Head Neck Surg . 2013;148[1]:S1‐S55), the guideline update group was convened with representation from the disciplines of otolaryngology–head and neck surgery, otology, neurotology, family medicine, audiology, emergency medicine, neurology, radiology, advanced practice nursing, and consumer advocacy. A systematic review of the literature was performed, and the prior clinical practice guideline on sudden hearing loss was reviewed in detail. Key Action Statements (KASs) were updated with new literature, and evidence profiles were brought up to the current standard. Research needs identified in the original clinical practice guideline and data addressing them were reviewed. Current research needs were identified and delineated. Results The guideline update group made strong recommendations for the following: (KAS 1) Clinicians should distinguish sensorineural hearing loss from conductive hearing loss when a patient first presents with sudden hearing loss. (KAS 7) Clinicians should educate patients with sudden sensorineural hearing loss about the natural history of the condition, the benefits and risks of medical interventions, and the limitations of existing evidence regarding efficacy. (KAS 13) Clinicians should counsel patients with sudden sensorineural hearing loss who have residual hearing loss and/or tinnitus about the possible benefits of audiologic rehabilitation and other supportive measures. These strong recommendations were modified from the initial clinical practice guideline for clarity and timing of intervention. The guideline update group made strong recommendations against the following: (KAS 3) Clinicians should not order routine computed tomography of the head in the initial evaluation of a patient with presumptive sudden sensorineural hearing loss. (KAS 5) Clinicians should not obtain routine laboratory tests in patients with sudden sensorineural hearing loss. (KAS 11) Clinicians should not routinely prescribe antivirals, thrombolytics, vasodilators, or vasoactive substances to patients with sudden sensorineural hearing loss. The guideline update group made recommendations for the following: (KAS 2) Clinicians should assess patients with presumptive sudden sensorineural hearing loss through history and physical examination for bilateral sudden hearing loss, recurrent episodes of sudden hearing loss, and/or focal neurologic findings. (KAS 4) In patients with sudden hearing loss, clinicians should obtain, or refer to a clinician who can obtain, audiometry as soon as possible (within 14 days of symptom onset) to confirm the diagnosis of sudden sensorineural hearing loss. (KAS 6) Clinicians should evaluate patients with sudden sensorineural hearing loss for retrocochlear pathology by obtaining magnetic resonance imaging or auditory brainstem response. (KAS 10) Clinicians should offer, or refer to a clinician who can offer, intratympanic steroid therapy when patients have incomplete recovery from sudden sensorineural hearing loss 2 to 6 weeks after onset of symptoms. (KAS 12) Clinicians should obtain follow‐up audiometric evaluation for patients with sudden sensorineural hearing loss at the conclusion of treatment and within 6 months of completion of treatment. These recommendations were clarified in terms of timing of intervention and audiometry and method of retrocochlear workup. The guideline update group offered the following KASs as options : (KAS 8) Clinicians may offer corticosteroids as initial therapy to patients with sudden sensorineural hearing loss within 2 weeks of symptom onset. (KAS 9a) Clinicians may offer, or refer to a clinician who can offer, hyperbaric oxygen therapy combined with steroid therapy within 2 weeks of onset of sudden sensorineural hearing loss. (KAS 9b) Clinicians may offer, or refer to a clinician who can offer, hyperbaric oxygen therapy combined with steroid therapy as salvage therapy within 1 month of onset of sudden sensorineural hearing loss. Differences from Prior Guideline Incorporation of new evidence profiles to include quality improvement opportunities, confidence in the evidence, and differences of opinion Included 10 clinical practice guidelines, 29 new systematic reviews, and 36 new randomized controlled trials Highlights the urgency of evaluation and initiation of treatment, if treatment is offered, by emphasizing the time from symptom occurrence Clarification of terminology by changing potentially unclear statements; use of the term sudden sensorineural hearing loss to mean idiopathic sudden sensorineural hearing loss to emphasize that &gt;90% of sudden sensorineural hearing loss is idiopathic sudden sensorineural hearing loss and to avoid confusion in nomenclature for the reader Changes to the KASs from the original guideline: KAS 1—When a patient first presents with sudden hearing loss, conductive hearing loss should be distinguished from sensorineural. KAS 2—The utility of history and physical examination when assessing for modifying factors is emphasized. KAS 3—The word “routine” is added to clarify that this statement addresses nontargeted head computerized tomography scan that is often ordered in the emergency room setting for patients presenting with sudden hearing loss. It does not refer to targeted scans, such as temporal bone computerized tomography scan, to assess for temporal bone pathology. KAS 4—The importance of audiometric confirmation of hearing status as soon as possible and within 14 days of symptom onset is emphasized. KAS 5—New studies were added to confirm the lack of benefit of nontargeted laboratory testing in sudden sensorineural hearing loss. KAS 6—Audiometric follow‐up is excluded as a reasonable workup for retrocochlear pathology. Magnetic resonance imaging, computerized tomography scan if magnetic resonance imaging cannot be done, and, secondarily, auditory brainstem response evaluation are the modalities recommended. A time frame for such testing is not specified, nor is it specified which clinician should be ordering this workup; however, it is implied that it would be the general or subspecialty otolaryngologist. KAS 7—The importance of shared decision making is highlighted, and salient points are emphasized. KAS 8—The option for corticosteroid intervention within 2 weeks of symptom onset is emphasized. KAS 9—Changed to KAS 9A and 9B. Hyperbaric oxygen the

This document updates the colorectal cancer (CRC) screening recommendations of the U.S. Multi-Society Task Force of Colorectal Cancer (MSTF), which represents the American College of Gastroenterology, the American Gastroenterological Association, and The American Society for Gastrointestinal Endoscopy. CRC screening tests are ranked in 3 tiers based on performance features, costs, and practical considerations. The first-tier tests are colonoscopy every 10 years and annual fecal immunochemical test (FIT). Colonoscopy and FIT are recommended as the cornerstones of screening regardless of how screening is offered. Thus, in a sequential approach based on colonoscopy offered first, FIT should be offered to patients who decline colonoscopy. Colonoscopy and FIT are recommended as tests of choice when multiple options are presented as alternatives. A risk-stratified approach is also appropriate, with FIT screening in populations with an estimated low prevalence of advanced neoplasia and colonoscopy screening in high prevalence populations. The second-tier tests include CT colonography every 5 years, the FIT-fecal DNA test every 3 years, and flexible sigmoidoscopy every 5 to 10 years. These tests are appropriate screening tests, but each has disadvantages relative to the tier 1 tests. Because of limited evidence and current obstacles to use, capsule colonoscopy every 5 years is a third-tier test. We suggest that the Septin9 serum assay (Epigenomics, Seattle, Wash) not be used for screening. Screening should begin at age 50 years in average-risk persons, except in African Americans in whom limited evidence supports screening at 45 years. CRC incidence is rising in persons under age 50, and thorough diagnostic evaluation of young persons with suspected colorectal bleeding is recommended. Discontinuation of screening should be considered when persons up to date with screening, who have prior negative screening (particularly colonoscopy), reach age 75 or have <10 years of life expectancy. Persons without prior screening should be considered for screening up to age 85, depending on age and comorbidities. Persons with a family history of CRC or a documented advanced adenoma in a first-degree relative age <60 years or 2 first-degree relatives with these findings at any age are recommended to undergo screening by colonoscopy every 5 years, beginning 10 years before the age at diagnosis of the youngest affected relative or age 40, whichever is earlier. Persons with a single first-degree relative diagnosed at ≥60 years with CRC or an advanced adenoma can be offered average-risk screening options beginning at age 40 years.

The BRAF V600E mutation has been associated with microsatellite instability and the CpG island methylator phenotype (CIMP) in colon cancer. We evaluated a large population-based sample of individuals with colon cancer to determine its relationship to survival and other clinicopathologic variables. The V600E BRAF mutation was seen in 5% (40 of 803) of microsatellite-stable tumors and 51.8% (43 of 83) of microsatellite-unstable tumors. In microsatellite-stable tumors, this mutation was related to poor survival, CIMP high, advanced American Joint Committee on Cancer (AJCC) stage, and family history of colorectal cancer [odds ratio, 4.23; 95% confidence interval (95% CI), 1.65-10.84]. The poor survival was observed in a univariate analysis of 5-year survival (16.7% versus 60.0%; P < 0.01); in an analysis adjusted for age, stage, and tumor site [hazard rate ratio (HRR), 2.97; 95% CI, 2.05-4.32]; in stage-specific, age-adjusted analyses for AJCC stages 2 to 4 (HRR, 4.88, 3.60, and 2.04, respectively); and in Kaplan-Meier survival estimates for AJCC stages 2 to 4 (P < 0.01 for all three stages). Microsatellite-unstable tumors were associated with an excellent 5-year survival whether the V600E mutation was present or absent (76.2% and 75.0%, respectively). We conclude that the BRAF V600E mutation in microsatellite-stable colon cancer is associated with a significantly poorer survival in stages 2 to 4 colon cancer but has no effect on the excellent prognosis of microsatellite-unstable tumors.

OBJECTIVE: To evaluate the efficacy of a physician-directed, nurse-managed, home-based case-management system for coronary risk factor modification. DESIGN: Randomized clinical trial in which patients received a special intervention (n = 293) or usual medical care (n = 292) during the first year after acute myocardial infarction. SETTING: 5 Kaiser Permanente Medical Centers in the San Francisco Bay area. PATIENTS: 585 men and women aged 70 years or younger who were hospitalized for acute myocardial infarction. INTERVENTION: In the hospital, specially trained nurses initiated interventions for smoking cessation, exercise training, and diet-drug therapy for hyperlipidemia. Intervention after discharge was implemented primarily by telephone and mail contact with patients in their homes. All medically eligible patients received exercise training; all smokers received the smoking cessation intervention; and all patients received dietary counseling and, if needed, lipid-lowering drug therapy. OUTCOME: Smoking prevalence and plasma low-density lipoprotein cholesterol (LDL) concentrations were measured 2 months after infarction, and functional capacity was measured 6 months after infarction. RESULTS: In the special intervention and usual care groups, the cotinine-confirmed smoking cessation rates were 70% and 53% (P = 0.03), plasma LDL cholesterol levels were 2.77 +/- 0.69 mmol/L and 3.41 +/- 0.90 mmol/L (107 +/- 30 mg/dL and 132 +/- 30 mg/dL) (P = 0.001), and functional capacities were 9.3 +/- 2.4 METS and 8.4 +/- 2.5 METS (P = 0.001), respectively. CONCLUSION: In a large health maintenance organization, a case-management system was considerably more effective than usual medical care for modification of coronary risk factors after myocardial infarction.

IMPORTANCE: Heart disease (HD) and cancer are the 2 leading causes of death in the United States. During the first decade of the 21st century, HD mortality declined at a much greater rate than cancer mortality and it appeared that cancer would overtake HD as the leading cause of death. OBJECTIVES: To determine whether changes in national trends had occurred in recent years in mortality rates due to all cardiovascular disease (CVD), HD, stroke, and cancer and to evaluate the gap between mortality rates from HD and cancer. DESIGN, SETTING, AND PARTICIPANTS: The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research data system was used to determine national trends in age-adjusted mortality rates due to all CVD, HD, stroke, and cancer from January 1, 2000, to December 31, 2011, and January 1, 2011, to December 31, 2014, overall, by sex, and by race/ethnicity. The present study was conducted from December 30, 2105, to January 18, 2016. MAIN OUTCOMES AND MEASURES: Comparison of annual rates of change and trend in gap between HD and cancer mortality rates. RESULTS: The rate of the decline in all CVD, HD, and stroke mortality decelerated substantially after 2011, and the rate of decline for cancer mortality remained relatively stable. Reported as percentage (95% CI), the annual rates of decline for 2000-2011 were 3.79% (3.61% to 3.97%), 3.69% (3.51% to 3.87%), 4.53% (4.34% to 4.72%), and 1.49% (1.37% to 1.60%) for all CVD, HD, stroke, and cancer mortality, respectively; the rates for 2011-2014 were 0.65% (-0.18% to 1.47%), 0.76% (-0.06% to 1.58%), 0.37% (-0.53% to 1.27%), and 1.55% (1.07% to 2.04%), respectively. Deceleration of the decline in all CVD mortality rates occurred in males, females, and all race/ethnicity groups. For example, the annual rates of decline for total CVD mortality for 2000-2011 were 3.69% (3.48% to 3.89%) for males and 3.98% (3.81% to 4.14%) for females; for 2011-2014, the rates were 0.23% (-0.71% to 1.16%) and 1.17% (0.41% to 1.93%), respectively. The gap between HD and cancer mortality persisted. CONCLUSIONS AND RELEVANCE: Deceleration in the decline of all CVD, HD, and stroke mortality rates has occurred since 2011. If this trend continues, strategic goals for lowering the burden of CVD set by the American Heart Association and the Million Hearts Initiative may not be reached.

The Multi-Society Task Force, in collaboration with invited experts, developed guidelines to assist health care providers with the appropriate provision of genetic testing and management of patients at risk for and affected with Lynch syndrome as follows: Figure 1 provides a colorectal cancer risk assessment tool to screen individuals in the office or endoscopy setting; Figure 2 illustrates a strategy for universal screening for Lynch syndrome by tumor testing of patients diagnosed with colorectal cancer; Figures 3,4,5,6 provide algorithms for genetic evaluation of affected and at-risk family members of pedigrees with Lynch syndrome; Table 10 provides guidelines for screening at-risk and affected persons with Lynch syndrome; and Table 12 lists the guidelines for the management of patients with Lynch syndrome. A detailed explanation of Lynch syndrome and the methodology utilized to derive these guidelines, as well as an explanation of, and supporting literature for, these guidelines are provided.

Because published outcome studies are the only available source of data about the morbidity among surviving very low birthweight infants (VLBW, less than 1500 g) a search was carried out of 1136 references in the English language. A total of 111 outcome studies were found that reported morbidity data in cohorts of VLBW infants born since 1960. The methods used and results obtained in these studies were systematically assessed. No agreement exists about the definition of study populations, descriptive statistics, or measurement of outcome. Follow up ranged from six months to 14 years. In 85 cohorts the incidence of cerebral palsy was recorded, and in 106 that of disability. Studies that followed up infants for longer time periods reported higher incidences of disability. Studies from the United States reported higher incidences of disability than those from other countries. The median incidence of cerebral palsy among all the cohorts studied was 7.7%, and the median incidence of disability was 25.0%. Despite substantial improvements in the mortality of VLBW infants, poor outcomes among survivors are common.

OBJECTIVE: To develop a quantitative model to estimate the probability of neonatal early-onset bacterial infection on the basis of maternal intrapartum risk factors. METHODS: This was a nested case-control study of infants born at ≥34 weeks' gestation at 14 California and Massachusetts hospitals from 1993 to 2007. Case-subjects had culture-confirmed bacterial infection at <72 hours; controls were randomly selected, frequency-matched 3:1 according to year and birth hospital. We performed multivariate analyses and split validation to define a predictive model based only on information available in the immediate perinatal period. RESULTS: We identified 350 case-subjects from a cohort of 608,014 live births. Highest intrapartum maternal temperature revealed a linear relationship with risk of infection below 100.5°F, above which the risk rose rapidly. Duration of rupture of membranes revealed a steadily increasing relationship with infection risk. Increased risk was associated with both late-preterm and postterm delivery. Risk associated with maternal group B Streptococcus colonization is diminished in the era of group B Streptococcus prophylaxis. Any form of intrapartum antibiotic given >4 hours before delivery was associated with decreased risk. Our model showed good discrimination and calibration (c statistic = 0.800 and Hosmer-Lemeshow P = .142 in the entire data set). CONCLUSIONS: A predictive model based on information available in the immediate perinatal period performs better than algorithms based on risk-factor threshold values. This model establishes a prior probability for newborn sepsis, which could be combined with neonatal physical examination and laboratory values to establish a posterior probability to guide treatment decisions.

OBJECTIVE: To define a quantitative stratification algorithm for the risk of early-onset sepsis (EOS) in newborns ≥ 34 weeks' gestation. METHODS: We conducted a retrospective nested case-control study that used split validation. Data collected on each infant included sepsis risk at birth based on objective maternal factors, demographics, specific clinical milestones, and vital signs during the first 24 hours after birth. Using a combination of recursive partitioning and logistic regression, we developed a risk classification scheme for EOS on the derivation dataset. This scheme was then applied to the validation dataset. RESULTS: Using a base population of 608,014 live births ≥ 34 weeks' gestation at 14 hospitals between 1993 and 2007, we identified all 350 EOS cases <72 hours of age and frequency matched them by hospital and year of birth to 1063 controls. Using maternal and neonatal data, we defined a risk stratification scheme that divided the neonatal population into 3 groups: treat empirically (4.1% of all live births, 60.8% of all EOS cases, sepsis incidence of 8.4/1000 live births), observe and evaluate (11.1% of births, 23.4% of cases, 1.2/1000), and continued observation (84.8% of births, 15.7% of cases, incidence 0.11/1000). CONCLUSIONS: It is possible to combine objective maternal data with evolving objective neonatal clinical findings to define more efficient strategies for the evaluation and treatment of EOS in term and late preterm infants. Judicious application of our scheme could result in decreased antibiotic treatment in 80,000 to 240,000 US newborns each year.

OBJECTIVES: To develop a risk-adjustment methodology that maximizes the use of automated physiology and diagnosis data from the time period preceding hospitalization. DESIGN: : Retrospective cohort study using split-validation and logistic regression. SETTING: Seventeen hospitals in a large integrated health care delivery system. SUBJECTS: Patients (n = 259,699) hospitalized between January 2002 and June 2005. MAIN OUTCOME MEASURES: Inpatient and 30-day mortality. RESULTS: Inpatient mortality was 3.50%; 30-day mortality was 4.06%. We tested logistic regression models in a randomly chosen derivation dataset consisting of 50% of the records and applied their coefficients to the validation dataset. The final model included sex, age, admission type, admission diagnosis, a Laboratory-based Acute Physiology Score (LAPS), and a COmorbidity Point Score (COPS). The LAPS integrates information from 14 laboratory tests obtained in the 24 hours preceding hospitalization into a single continuous variable. Using Diagnostic Cost Groups software, we categorized patients as having up to 40 different comorbidities based on outpatient and inpatient data from the 12 months preceding hospitalization. The COPS integrates information regarding these 41 comorbidities into a single continuous variable. Our best model for inpatient mortality had a c statistic of 0.88 in the validation dataset, whereas the c statistic for 30-day mortality was 0.86; both models had excellent calibration. Physiologic data accounted for a substantial proportion of the model's predictive ability. CONCLUSION: Efforts to support improvement of hospital outcomes can take advantage of risk-adjustment methods based on automated physiology and diagnosis data that are not confounded by information obtained after hospital admission.

Adenomatous polyps are the most common neoplastic findings uncovered in people who undergo colorectal screening or have a diagnostic workup for symptoms. It was common practice in the 1970s for these patients to have annual follow-up surveillance examinations to detect additional new adenomas as well as missed synchronous adenomas. As a result of the National Polyp Study report in 1993, which demonstrated clearly in a randomized design that the first postpolypectomy examination could be deferred for 3 years, guidelines published by a gastrointestinal consortium in 1997 recommended that the first follow-up surveillance be 3 years after polypectomy for most patients. In 2003, these guidelines were updated, colonoscopy was recommended as the only follow-up examination, and stratification at baseline into lower and higher risk for subsequent adenomas was suggested. The 1997 and 2003 guidelines dealt with both screening and surveillance. However, it has become increasingly clear that postpolypectomy surveillance is now a large part of endoscopic practice, draining resources from screening and diagnosis. In addition, surveys have demonstrated that a large proportion of endoscopists are conducting surveillance examinations at shorter intervals than recommended in the guidelines. In the present paper, a careful analytic approach was designed addressing all evidence available in the literature to delineate predictors of advanced pathology, both cancer and advanced adenomas, so that patients can be more definitely stratified at their baseline colonoscopy into those at lower or increased risk for a subsequent advanced neoplasia. People at increased risk have either three or more adenomas, or high-grade dysplasia, or villous features, or an adenoma > or =1 cm in size. It is recommended that they have a 3-year follow-up colonoscopy. People at lower risk who have one or two small (< 1 cm) tubular adenomas with no high-grade dysplasia can have a follow-up in 5 to 10 years, whereas people with hyperplastic polyps only should have a 10-year follow-up as average-risk people. Recent papers have reported a significant number of missed cancers by colonoscopy. However, high-quality baseline colonoscopy with excellent patient preparation and adequate withdrawal time should minimize this and reduce clinicians' concerns. These guidelines were developed jointly by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society to provide a broader consensus and thereby increase utilization of the recommendations by endoscopists. Adoption of these guidelines nationally can have a dramatic impact on shifting available resources from intensive surveillance to screening. It has been shown that the first screening colonoscopy and polypectomy produces the greatest effects on reducing the incidence of colorectal cancer in patients with adenomatous polyps.

OBJECTIVE: Macrosomia is associated with adverse maternal outcomes. The objective of this study was to characterize the epidemiology of macrosomia and related maternal complications. METHOD: Live births (146,526) were identified between 1995 and 1999 in the Kaiser Permanente Medical Care Program's Northern California Region (KPMCP NCR) database. Bivariate and multivariate analyses were performed for risk factors and complications associated with macrosomia (birth weight >4500 g). RESULT: Male infant sex, multiparity, maternal age 30-40, white race, diabetes, and gestational age >41 weeks were associated with macrosomia (p<0.001). In bivariate and multivariate analyses, macrosomia was associated with higher rates of cesarean birth, chorioamnionitis, shoulder dystocia, fourth-degree perineal lacerations, postpartum hemorrhage, and prolonged hospital stay (p<0.01). CONCLUSION: Macrosomia was associated with adverse maternal outcomes in this cohort. More research is needed to determine how to prevent complications related to excessive birth weight.

Importance: Musculoskeletal symptoms are the most common adverse effects of aromatase inhibitors and often result in therapy discontinuation. Small studies suggest that acupuncture may decrease aromatase inhibitor-related joint symptoms. Objective: To determine the effect of acupuncture in reducing aromatase inhibitor-related joint pain. Design, Setting, and Patients: Randomized clinical trial conducted at 11 academic centers and clinical sites in the United States from March 2012 to February 2017 (final date of follow-up, September 5, 2017). Eligible patients were postmenopausal women with early-stage breast cancer who were taking an aromatase inhibitor and scored at least 3 on the Brief Pain Inventory Worst Pain (BPI-WP) item (score range, 0-10; higher scores indicate greater pain). Interventions: Patients were randomized 2:1:1 to the true acupuncture (n = 110), sham acupuncture (n = 59), or waitlist control (n = 57) group. True acupuncture and sham acupuncture protocols consisted of 12 acupuncture sessions over 6 weeks (2 sessions per week), followed by 1 session per week for 6 weeks. The waitlist control group did not receive any intervention. All participants were offered 10 acupuncture sessions to be used between weeks 24 and 52. Main Outcomes and Measures: The primary end point was the 6-week BPI-WP score. Mean 6-week BPI-WP scores were compared by study group using linear regression, adjusted for baseline pain and stratification factors (clinically meaningful difference specified as 2 points). Results: Among 226 randomized patients (mean [SD] age, 60.7 [8.6] years; 88% white; mean [SD] baseline BPI-WP score, 6.6 [1.5]), 206 (91.1%) completed the trial. From baseline to 6 weeks, the mean observed BPI-WP score decreased by 2.05 points (reduced pain) in the true acupuncture group, by 1.07 points in the sham acupuncture group, and by 0.99 points in the waitlist control group. The adjusted difference for true acupuncture vs sham acupuncture was 0.92 points (95% CI, 0.20-1.65; P = .01) and for true acupuncture vs waitlist control was 0.96 points (95% CI, 0.24-1.67; P = .01). Patients in the true acupuncture group experienced more grade 1 bruising compared with patients in the sham acupuncture group (47% vs 25%; P = .01). Conclusions and Relevance: Among postmenopausal women with early-stage breast cancer and aromatase inhibitor-related arthralgias, true acupuncture compared with sham acupuncture or with waitlist control resulted in a statistically significant reduction in joint pain at 6 weeks, although the observed improvement was of uncertain clinical importance. Trial Registration: ClinicalTrials.gov Identifier: NCT01535066.

BACKGROUND: Few data are available on the outcome of neonatal sepsis evaluations in an era when intrapartum antibiotic therapy is common. METHODS: We identified all newborns weighing >/=2000 g at birth who were ever evaluated for suspected bacterial infection at 6 Kaiser Permanente hospitals between October 1995 and November 1996, reviewed their records and laboratory data, and tracked them to 1 week after discharge. We analyzed the relationship between key predictors and the presence of neonatal bacterial infection. RESULTS: Among 18 299 newborns >/=2000 g without major congenital anomalies, 2785 (15.2%) were evaluated for sepsis with a complete blood count and/or blood culture. A total of 62 (2.2%) met criteria for proven, probable, or possible bacterial infection: 22 (.8%) had positive cultures and 40 (1.4%) had clinical evidence of bacterial infection. We tracked all but 10 infants (.4%) to 7 days postdischarge. There were 67 rehospitalizations (2.4%; 2 for group B streptococcus bacteremia). Among 1568 infants who did not receive intrapartum antibiotics, initial asymptomatic status was associated with decreased risk of infection (adjusted odds ratio [AOR]:.26; 95% confidence interval [CI]:.11-.63), while chorioamnionitis (AOR: 2. 40; 95% CI: 1.15-5.00), low absolute neutrophil count (AOR: 2.84; 95% CI: 1.50-5.38), and meconium-stained amniotic fluid (AOR: 2.23; 95% CI: 1.18-4.21) were associated with increased risk. Results were similar among 1217 infants who were treated, except that maternal chorioamnionitis was not significantly associated with neonatal infection. CONCLUSIONS: The risk of bacterial infection in asymptomatic newborns is low. Evidence-based observation and treatment protocols could be defined based on a limited set of predictors: maternal fever, chorioamnionitis, initial neonatal examination, and absolute neutrophil count. Many missed opportunities for treating mothers and infants exist.

Importance: Many patients with diabetic peripheral neuropathy experience chronic pain and inadequate relief despite best available medical treatments. Objective: To determine whether 10-kHz spinal cord stimulation (SCS) improves outcomes for patients with refractory painful diabetic neuropathy (PDN). Design, Setting, and Participants: The prospective, multicenter, open-label SENZA-PDN randomized clinical trial compared conventional medical management (CMM) with 10-kHz SCS plus CMM. Participants with PDN for 1 year or more refractory to gabapentinoids and at least 1 other analgesic class, lower limb pain intensity of 5 cm or more on a 10-cm visual analogue scale (VAS), body mass index (calculated as weight in kilograms divided by height in meters squared) of 45 or less, hemoglobin A1c (HbA1c) of 10% or less, daily morphine equivalents of 120 mg or less, and medically appropriate for the procedure were recruited from clinic patient populations and digital advertising. Participants were enrolled from multiple sites across the US, including academic centers and community pain clinics, between August 2017 and August 2019 with 6-month follow-up and optional crossover at 6 months. Screening 430 patients resulted in 214 who were excluded or declined participation and 216 who were randomized. At 6-month follow-up, 187 patients were evaluated. Interventions: Implanted medical device delivering 10-kHz SCS. Main Outcomes and Measures: The prespecified primary end point was percentage of participants with 50% pain relief or more on VAS without worsening of baseline neurological deficits at 3 months. Secondary end points were tested hierarchically, as prespecified in the analysis plan. Measures included pain VAS, neurological examination, health-related quality of life (EuroQol Five-Dimension questionnaire), and HbA1c over 6 months. Results: Of 216 randomized patients, 136 (63.0%) were male, and the mean (SD) age was 60.8 (10.7) years. Additionally, the median (interquartile range) duration of diabetes and peripheral neuropathy were 10.9 (6.3-16.4) years and 5.6 (3.0-10.1) years, respectively. The primary end point assessed in the intention-to-treat population was met by 5 of 94 patients in the CMM group (5%) and 75 of 95 patients in the 10-kHz SCS plus CMM group (79%; difference, 73.6%; 95% CI, 64.2-83.0; P < .001). Infections requiring device explant occurred in 2 patients in the 10-kHz SCS plus CMM group (2%). For the CMM group, the mean pain VAS score was 7.0 cm (95% CI, 6.7-7.3) at baseline and 6.9 cm (95% CI, 6.5-7.3) at 6 months. For the 10-kHz SCS plus CMM group, the mean pain VAS score was 7.6 cm (95% CI, 7.3-7.9) at baseline and 1.7 cm (95% CI, 1.3-2.1) at 6 months. Investigators observed neurological examination improvements for 3 of 92 patients in the CMM group (3%) and 52 of 84 in the 10-kHz SCS plus CMM group (62%) at 6 months (difference, 58.6%; 95% CI, 47.6-69.6; P < .001). Conclusions and Relevance: Substantial pain relief and improved health-related quality of life sustained over 6 months demonstrates 10-kHz SCS can safely and effectively treat patients with refractory PDN. Trial Registration: ClincalTrials.gov Identifier: NCT03228420.

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States (1) Colonoscopy can prevent CRC by the detection and removal of precancerous lesions. In addition to CRC screening and surveillance, colonoscopy is used widely for the diagnostic evaluation of symptoms and other positive CRC screening tests. Regardless of indication, the success of colonoscopy is linked closely to the adequacy of preprocedure bowel cleansing. Unfortunately, up to 20–25% of all colonoscopies are reported to have an inadequate bowel preparation (2, 3) The reasons for this range from patient-related variables such as compliance with preparation instructions and a variety of medical conditions that make bowel cleansing more difficult to unit-specific factors (eg, extended wait times after scheduling of colonoscopy) (4) Adverse consequences of ineffective bowel preparation include lower adenoma detection rates, longer procedural time, lower cecal intubation rates, increased electrocautery risk, and shorter intervals between examinations (3, 5, 6, 7) Bowel preparation formulations intended for precolonoscopy cleansing are assessed based on their efficacy, safety, and tolerability. Lack of specific organ toxicity is considered to be a prerequisite for bowel preparations. Between cleansing efficacy and tolerability, however, the consequences of inadequate cleansing suggest that efficacy should be a higher priority than tolerability. Consequently, the choice of a bowel cleansing regimen should be based on cleansing efficacy first and patient tolerability second. However, efficacy and tolerability are closely interrelated. For example, a cleansing agent that is poorly tolerated and thus not fully ingested may not achieve an adequate cleansing. The goals of this consensus document are to provide expert, evidence-based recommendations for clinicians to optimize colonoscopy preparation quality and patient safety. Recommendations are provided using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) scoring system, which weighs the strength of the recommendation and the quality of the evidence (8) Methods Search Strategy Computerized medical literature searches were conducted from January 1980 (first year of approval of polyethylene glycol–electrolyte lavage solution [PEG-ELS]–based preparation by the Food and Drug Administration [FDA]) up to August 2013 using MEDLINE, PubMed EMBASE, Scopus, CENTRAL, and ISI Web of knowledge. We used a highly sensitive search strategy to identify reports of randomized controlled trials (9) with a combination of medical subject headings adapted to each database and text words related to colonoscopy and gastrointestinal agents, bowel preparation, generic name, and brand name. The complete search terms are available in Appendix A. Recursive searches and cross-referencing also were performed using a “similar articles” function; hand searches of articles were identified after an initial search. We included all fully published adult human studies in English or French. A systematic review of published articles and abstracts presented at national meetings was performed to collect and select the evidence. A meta-analysis and consensus agreement were used to analyze the evidence. Expert consensus was used to formulate the recommendations. The GRADE system was used to rate the strength of the recommendations. The guideline was reviewed by committees of and approved by the governing boards of the member societies of the Multi-Society Task Force on Colorectal Cancer (American College of Gastroenterology, American Gastroenterological Association, and American Society of Gastrointestinal Endoscopy). Effect of inadequate preparation on polyp/adenoma detection and recommended follow-up intervals Recommendations Preliminary assessment of preparation quality should be made in the rectosigmoid colon, and if the indication is screening or surveillance and the preparation clearly is inadequate to allow polyp detection greater than 5 mm, the procedure should be either terminated and rescheduled or an attempt should be made at additional bowel cleansing strategies that can be delivered without cancelling the procedure that day (Strong recommendation, low-quality evidence). If the colonoscopy is complete to cecum, and the preparation ultimately is deemed inadequate, then the examination should be repeated, generally with a more aggressive preparation regimen, within 1 year; intervals shorter than 1 year are indicated when advanced neoplasia is detected and there is inadequate preparation (Strong recommendation, low-quality evidence). If the preparation is deemed adequate and the colonoscopy is completed then the guideline recommendations for screening or surveillance should be followed (Strong recommendation, high-quality evidence). Inadequate colonic preparation is associated with reduced adenoma detection rates (ADRs). A large prospective European study of 5832 patients enrolled in 21 centers across 11 countries examined the association of preparation quality and polyp identification during colonoscopy performed for a range of common indications. High-quality preparation was associated with identification of polyps of all sizes (odds ratio [OR], 1.73; 95% confidence interval [CI], 1.28–2.36), and with polyps greater than 10 mm in size (OR, 1.72; 95% CI, 1.11–2.67) (2) An analysis of a national endoscopic database examined the association of preparation quality and polyp identification in 93,004 colonoscopies (3) Colon preparation (as entered by the endoscopist at the time of the procedure) was dichotomized into adequate (excellent, good, and fair/adequate) and inadequate (fair, inadequate, and poor). In adjusted models, adequate preparation was predictive of detection of all polyps (OR, 1.21; 95% CI, 1.16–1.25), but not polyps greater than 9 mm and/or suspected cancer (OR, 1.5; 95% CI, 0.98–1.11). Similarly, a single-center study based at a US Veterans Affairs Medical Center examined preparation quality and ADRs in 8800 colonoscopies performed between 2001 and 2010 (10) When comparing those examinations with an inadequate/poor preparation (n=829) with those with an adequate preparation (n=5162), overall polyp detection was reduced (OR, 0.66; 95% CI, 0.56–0.83). Two retrospective single-center studies examined the association of preparation quality and adenoma miss rates when the preparation was considered inadequate and the examination was repeated within a short interval (11, 12) Miss rates were the total adenomas found on the second examination divided by the total adenomas found on both examinations. In 1 study (11) there were 12,787 colonoscopies with 3047 (24%) suboptimal preparations (fair or poor). Repeat colonoscopy within 3 years in 216 individuals who achieved adequate preparation showed an overall adenoma miss rate of 42%, and a miss rate of 27% for lesions 10 mm or larger in size. The other study identified 373 average-risk screening patients with poor or inadequate preparation (12) Repeat colonoscopy in 133 patients (77% achieved excellent or good preparation) showed a overall adenoma miss A prospective study individuals after a complete colonoscopy and then a colonoscopy within 3 of the initial examination The patient adenoma miss rate increased as preparation quality on the In the patients with poor preparation the adenoma and advanced adenoma miss rates were and with and in those with excellent preparation that in the of a poor preparation, recommendations for follow-up evaluation and on shorter intervals In 1 study and were of preparations of to a preparation, a interval generally was recommended for a screening However, recommendations were for the from more than 5 years to an A of for found that follow-up evaluation in 3 years or for adenomas and a suboptimal preparation studies have examined recommendations for follow-up evaluation within the of study from in on in each quality was not reported in of the examinations. Bowel preparations than excellent were associated with more aggressive surveillance for those found with polyps or and/or A prospective single-center study of patients showed that when a poor preparation recommended follow-up intervals that more were with A prospective study that for each of bowel preparations deemed inadequate and colonoscopy at a the of colonoscopy overall were increased by of inadequate preparation are the for a for rates of adequate preparation and of cleansing Recommendations of a bowel cleansing regimen is recommended for colonoscopy (Strong recommendation, high-quality evidence). A regimen is an to for patients an examination (Strong recommendation, high-quality evidence). The second of preparation should the time of colonoscopy with of the at the procedure time (Strong recommendation, evidence). When preparation are the day from the the and a that the and detection of lesions. The of time between the of preparation and the of colonoscopy with the quality of the cleansing In 1 study the of good or excellent preparation of the by up to for each additional between the of the preparation and the of the colonoscopy that of the bowel cleansing is on the day of the efficacy with a with the regimen of the preparation the day the procedure to higher ADRs have of preparations for colonoscopy bowel cleansing is an to for patients with an colonoscopy In a prospective preparation provided on of and greater patient with to and and of for An guideline from the American Society of however, that of not endoscopic studies found that of bowel cleansing on the day of colonoscopy not that the rate of of bowel preparations is to other may be a greater than A second to is that patients for may be to up during the to the second of of and compliance with bowel preparation is and should not a to preparations for colonoscopy The of during to the is increased with during bowel cleansing Recommendation using a bowel cleansing regimen, recommendations can include either or the on the day colonoscopy recommendation, evidence). patients are to the day randomized trials that a the day colonoscopy is associated with of the preparation and or bowel cleansing The in trials were and included a and a and a this of are to a the day a for or all of the day colonoscopy can be considered for patients without other for inadequate additional should in efficacy if is of patient and for preparation Recommendations should provide both and patient instructions for all of the colonoscopy preparation and the of compliance (Strong recommendation, evidence). The the colonoscopy should that and are in for patients to achieve adequate colonoscopy preparation quality (Strong recommendation, low-quality evidence). A patient by patient and examinations and The of both and with instructions is an of adequate bowel preparation such as and should be and and should be across a range of and The of a patient on precolonoscopy preparation in bowel preparation quality than those achieved using instructions (OR, 95% CI, patient patients the colonoscopy provide to to review bowel preparation and and that patients have an for for in in an for screening colonoscopy rates In the of are by increased screening compliance and is to included and The of the and of the patient additional the quality of bowel preparation during colonoscopy Recommendations of bowel preparation should be assessed after all to have completed (Strong recommendation, low-quality evidence). of the rate of adequate cleansing should be conducted (Strong recommendation, evidence). preparation, as cleansing that a recommendation of a screening or surveillance interval to the of the should be achieved in or more of all examinations on a (Strong recommendation, low-quality evidence). the quality of the bowel preparation is a of the colonoscopy In trials cleansing quality is using that quality for In however, and of the in the can be by cleansing. the to is after the preparation quality in should be assessed after and For this the of a bowel preparation that scoring (eg, is not The US Multi-Society Task Force the of an adequate preparation is in which the can and a follow-up screening or surveillance interval for the colonoscopy that is for the examination Unfortunately, the in that to the at which the preparation the of an adequate preparation to the recommended screening or surveillance generally are In clinicians an of good, and In this excellent and good are widely as but that preparations in also are adequate (10) The recommended that clinicians the preparation adequate if after and the during the procedure was deemed adequate for the detection of lesions greater than 5 mm in size is not of a bowel preparation but the sizes of lesions that are to is to for scoring bowel cleansing that not and include that to adequate the Bowel to not and a Bowel of 5 or higher was associated with a rate of follow-up intervals A review of bowel preparation is in Appendix is used in that the for an adequate preparation should include the the screening or surveillance intervals based on the colonoscopy and that the to lesions greater than 5 mm in size the is a of adequacy and to screening and surveillance are to procedure reports into a that and quality national and of If the rate of adequate bowel preparation for an endoscopist is the recommended of an should be rates of inadequate preparations can patient to preparation for medical of inadequate preparation, or that and of the preparations Recommendations of a regimen should into the medical when the adequacy of bowel preparation reported from colonoscopies (Strong recommendation, evidence). A regimen of high-quality bowel cleansing (Strong recommendation, high-quality evidence). In a a quality that is not to a (Strong recommendation, high-quality evidence). glycol–electrolyte lavage solution cleansing are available in large or or as an solution and is a cleansing agent that was from the US in of A of a the of to the approved include solution and a combination of and glycol–electrolyte lavage solution formulations were to of preparations with was from the and preparations have approved by the and which is was with in trials patients trials included not a in bowel (OR, 95% CI, trials included a in which were the day and were the day of the procedure with a regimen of patients trials were in increased for the regimen with the (OR, 95% CI, are are considered in patients who are to patients with and advanced solution Two trials in a regimen with the day and found more preparations with The second with and were more when in and the approved for The of patients found that not bowel (OR, 95% CI, a with a was to the US after in and trials and patients The preparations were either with or trials included comparing with The not a in efficacy with (OR, 95% CI, trials with patients trials included was not to (OR, 95% CI, 1 the regimen the day or the day patients not with or regimen a higher of bowel (OR, 95% CI, for bowel preparation of the of from of factors for include the inadequate during bowel preparation, reduced time interval between the of and and trials were included in a of patients trials included The of not an in bowel (OR, 95% CI, but was associated with to the regimen (OR, 95% CI, of with and were trials were included in the of the regimen with the day the procedure or the day for a total of patients Two included and showed cleansing with (OR, 95% CI, is and tolerated by the of as a is not recommended in patients with or or or should be used in to patients who are or or preparations Recommendations The bowel cleansing have efficacy that from adequate to on the of and is used or in of the the efficacy and tolerability are with a regimen (Strong recommendation, evidence). the generally are is when using in for example, preparations and should be in patients with recommendation, quality evidence). The of for bowel cleansing colonoscopy is deemed to be for by the without from a The efficacy and of for specific may be the of generally is conducted by than for Consequently, an may have or evidence or either efficacy or to other available for colonoscopy bowel preparation be in randomized trials to their efficacy and and then approval a Drug from the are available by For a agent to be without an approved the for as in the The bowel cleansing and with an approved and/or to the are as and and and or can be recommended by as of a regimen in patients for or for the for or endoscopic The available on that have used for bowel cleansing an for is available as an When used for a precolonoscopy bowel preparation, the of 1 are with of to a In clinicians or in with the randomized controlled trials have either or with an with available In 1 cleansing was with than with In the 1 study that used than the of patients an adequate bowel preparation was with and based on and overall was with than with in studies and in tolerability was in 1 Adverse with overall are is a when using a lavage solution such as in were in 3 studies that of have when the but not with of for bowel preparation to have but additional evaluation of and is and a widely used agent in the United was in randomized trials that with either or solution 3) was to solution good or excellent quality cleansing in and of patients in the and colon, A in may be but not reported to cause in The of preparations in patients with should be of toxicity A regimen is in such was in randomized controlled either or with comparing with either or of was as as in patients more and with to cleansing In randomized trials that with achieved lower rates of bowel cleansing tolerability for and solution was with the of which was more common with to cleansing colonoscopy Recommendation The of for bowel cleansing colonoscopy is not recommended recommendation, evidence). agents, intended to and/or of the have for precolonoscopy cleansing of the have included (eg, and have efficacy, safety, or tolerability of the bowel the of for colonic cleansing colonoscopy is not but the may be in select at the of the is the agent for bowel cleansing. In a meta-analysis of randomized trials comparing colonoscopy bowel with or without the addition of the overall efficacy of preparation was (OR, 95% CI, a in the of (OR, 95% CI, in the The of between from or of a solution In randomized such as and have not patient tolerability or quality of the bowel preparation and in preprocedure tolerability with in and and efficacy in patients preparations as a in preparation quality or when with in a randomized of patients and have used as to with tolerability the quality of the bowel preparation was not as with was in a randomized comparing preparations. with and showed tolerability, safety, and compliance randomized study of patients showed cleansing with with with When with or formulations have adequate bowel cleansing but across studies followed by cleansing quality in the colon, but in the with The of was to and of A of a and in patients cleansing with but in patients with in patient to Recommendations bowel cleansing is associated with greater to regimen with the day regimen (Strong recommendation, high-quality evidence). The of bowel cleansing is associated with greater to a colonoscopy (Strong recommendation, high-quality evidence). from 5 randomized trials showed patient and with preparation (OR, 95% CI, with a regimen increased the of adequate bowel preparations (OR, 95% CI, in compliance was in randomized patients for colonoscopy who and symptoms such as and were more in the In trials of with to bowel cleansing regimen was lower in the (OR, 95% CI, and higher for the (OR, 95% CI, For to was not reported in of the studies to the preparation was higher with than with (OR, 95% CI, and was not reported in the 1 comparing a regimen a or regimen In the studies comparing with to was higher with A prospective study examined symptoms after colonoscopy in who completed a at and after or in in the after and in between and (OR, 95% CI, and longer procedure 95% CI, 95% CI, 95% CI, were associated with or from for the colonoscopy preparation, or of bowel preparation in specific Recommendations is evidence to specific bowel preparation for however, that preparations be in this (Strong recommendation, low-quality evidence). is evidence to specific bowel preparation for and however, that preparations should not be used in than or in those with factors for from this (Strong recommendation, quality evidence). should be in patients with or suspected bowel recommendation, quality evidence). bowel should be considered in patients with factors for inadequate preparation (eg, patients with a inadequate preparation, of of or other or recommendation, low-quality A of patient factors that inadequate preparation is presented in Appendix preparations or extended time for preparations are recommended for patients after recommendation, quality evidence). should be used to the for in (Strong recommendation, quality evidence). is evidence to specific for with a of additional bowel should be considered recommendation, quality evidence). of individuals may from the bowel preparation regimen of tolerability, or related to the advanced is a of suboptimal bowel preparation, overall of the bowel preparation is between and patients colonoscopy In trials of and randomized to either or there was in tolerability or quality of the bowel cleansing however, more in the in 1 study and associated have reported in the was associated with of in patients A large retrospective study of individuals than who colonoscopy in reported that or within of colonoscopy were between those or for each of bowel preparation for patients should be to the and or to with the specific of adequate during colonoscopy preparation is in controlled trials of bowel preparation have performed in have is of for with the of a is for with or bowel can bowel preparation with lavage or and In a study of followed by at a of in after and were common 11 of the in this study of the lavage of the In a randomized study comparing 3 with an the solution in the cleansing but was tolerated used in is at a of for the with a on the day in combination with an using a preparation, also have there are controlled trials using this agent in In a randomized comparing a preparation of and with in the preparation was tolerated with cleansing randomized study comparing with with in addition to found that the regimen was to the regimen is associated with tolerability and in with or with The bowel cleansing of was to in 1 study and in study In a randomized study comparing a and with the tolerability, the quality of cleansing was with the regimen The Society of and reviewed the evidence of with and recommended that should not be used in than years of with of with that with (eg, and at for or and with or suspected The Society of and recommended as cleansing for and bowel The of bowel preparations can be associated with the of that may of bowel In a prospective study of patients without bowel lesions from were reported in In a in reported that was greater with and with In in lesions were reported in of patients with of patients who solution may the of the is and from bowel is published evidence to specific for with a of with should be to or if preparations are used the for to be In patients should be to and to symptoms related to from the Colonoscopy is indicated during If should be the second and should have a indication with a assessment of the and efficacy of bowel preparations have not in this The US of for of during and are of were reported to be in a study of patients who were for of and was reported in a of a who during The American Gastroenterological that should be the American Society of Gastrointestinal that preparations should be used with to and found that of have or to a patient with of In of of the have or an preparation in a is considered a are recommended by the American Gastroenterological for lower colonoscopy is indicated during for inadequate preparation is evidence to a strategy for those patients with a poor preparation that of the The can be considered in such Recommendations can be for patients on the day of compliance with the regimen recommendation, quality evidence). with colonoscopy on the day can be for those patients who recommendation, quality evidence). the patient from and with of with or colonoscopy associated with than colonoscopy recommendation, low-quality evidence). studies have factors for inadequate preparation, a study examined such factors for a second In patients who a second colonoscopy of inadequate preparation, the second examination of inadequate preparation in of those patients colonoscopy to other was associated with a reduced of (OR, 95% CI, individuals to have a poor preparation at the time of to the allow for study found that those or a of a or poor preparation In such preparation with or additional preparation be Two studies the of a as a regimen during colonoscopy In each the patients are from and then to the to The of the studies of the in 21 found to have inadequate preparation the as as either a followed by a or were into the the of the The reported success in all The other study in the was used to the quality of the preparation in the rectosigmoid For those to have poor or inadequate preparation, a was at the of the the using this of were or In each the colonoscopy was completed reported on adult patients with a colonoscopy as a of inadequate preparation in then an strategy the second The Bowel was at the time of the initial colonoscopy and those with a of or 1 on were deemed The bowel regimen in included a for followed by a on the day the the of the 10 of was with of A second of was on the day of the using this of an adequate preparation as assessed by the Bowel each the on of patients with inadequate preparation are A variety of that additional or are to be at colonoscopy and on as as deemed are to in patients to follow-up who to the with are at increased of inadequate preparation and may more or attempt at bowel cleansing for colonoscopy in precancerous lesions and increased related to and tolerability of bowel preparations are and related but efficacy is of of the consequences of inadequate cleansing. bowel preparation that the a screening or surveillance interval with the of the examination and screening and surveillance The rate of adequate bowel cleansing should be at and higher of medical factors that the of inadequate preparation and factors that poor compliance with instructions can to the of more or aggressive preparation or more patients who with inadequate preparation can have their by additional cleansing on the day of the Bowel preparation quality should be after to cleansing quality have The are from the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal document was approved by the governing of 3 is the of in by from The Veterans The in this not the of the of Veterans the as a and for as a for and as a for A. as a for and and from and as a and on the and from and as a for a and for as a for on the boards for and and as a for and and as a for and and as a for and and on the for The

BACKGROUND: The neurodevelopmental risks associated with high total serum bilirubin levels in newborns are not well defined. METHODS: We identified 140 infants with neonatal total serum bilirubin levels of at least 25 mg per deciliter (428 micromol per liter) and 419 randomly selected controls from a cohort of 106,627 term and near-term infants born from 1995 through 1998 in Kaiser Permanente hospitals in northern California. Data on outcomes were obtained from electronic records, interviews, responses to questionnaires, and neurodevelopmental evaluations that had been performed in a blinded fashion. RESULTS: Peak bilirubin levels were between 25 and 29.9 mg per deciliter (511 micromol per liter) in 130 of the newborns with hyperbilirubinemia and 30 mg per deciliter (513 micromol per liter) or more in 10 newborns; treatment involved phototherapy in 136 cases and exchange transfusion in 5. Follow-up data to the age of at least two years were available for 132 of 140 children with a history of hyperbilirubinemia (94 percent) and 372 of 419 controls (89 percent) and included formal evaluation at a mean (+/-SD) age of 5.1+/-0.12 years for 82 children (59 percent) and 168 children (40 percent), respectively. There were no cases of kernicterus. Neither crude nor adjusted scores on cognitive tests differed significantly between the two groups; on most tests, 95 percent confidence intervals excluded a 3-point (0.2 SD) decrease in adjusted scores in the hyperbilirubinemia group. There was no significant difference between groups in the proportion of children with abnormal neurologic findings on physical examination or with documented diagnoses of neurologic abnormalities. Fourteen of the children with hyperbilirubinemia (17 percent) had "questionable" or abnormal findings on neurologic examination, as compared with 48 controls (29 percent; P=0.05; adjusted odds ratio, 0.47; 95 percent confidence interval, 0.23 to 0.98; P=0.04). The frequencies of parental concern and reported behavioral problems also were not significantly different between the two groups. Within the hyperbilirubinemia group, those with positive direct antiglobulin tests had lower scores on cognitive testing but not more neurologic or behavioral problems. CONCLUSIONS: When treated with phototherapy or exchange transfusion, total serum bilirubin levels in the range included in this study were not associated with adverse neurodevelopmental outcomes in infants born at or near term.

BACKGROUND: A complete blood count (CBC) with white blood cell differential is commonly ordered to evaluate newborns at risk for sepsis. OBJECTIVES: To quantify how well components of the CBC predict sepsis in the first 72 hours after birth. METHODS: For this retrospective cross-sectional study we identified 67 623 term and late-preterm (≥ 34 weeks gestation) newborns from 12 northern California Kaiser hospitals and 1 Boston, Massachusetts hospital who had a CBC and blood culture within 1 hour of each other at <72 hours of age. We compared CBC results among newborns whose blood cultures were and were not positive and quantified discrimination by using receiver operating characteristic curves and likelihood ratios. RESULTS: Blood cultures of 245 infants (3.6 of 1000 tested newborns) were positive. Mean white blood cell (WBC) counts and mean absolute neutrophil counts (ANCs) were lower, and mean proportions of immature neutrophils were higher in newborns with infection; platelet counts did not differ. Discrimination improved with age in the first few hours, especially for WBC counts and ANCs (eg, the area under the receiver operating characteristic curve for WBC counts was 0.52 at <1 hour and 0.87 at ≥ 4 hours). Both WBC counts and ANCs were most informative when very low (eg, the likelihood ratio for ANC < 1000 was 115 at ≥ 4 hours). No test was very sensitive; the lowest likelihood ratio (for WBC count ≥ 20 000 at ≥ 4 hours) was 0.16. CONCLUSION: Optimal interpretation of the CBC requires using interval likelihood ratios for the newborn's age in hours.